More than 9 months after breaking up with Pfizer, Haizheng Pharmaceuticals has re-emerged out of stock

Haizheng Pharmaceuticals reproduces the phenomenon of out-of-stock.
An exclusive letter to experts from a reporter for Securities Daily, a communication note on the temporary tight supply of Rui Yining (hereinafter referred to as the Communication Note), shows that Reynin's semi-finished medicine is manufactured by Pfizer's Puerto Rico plant, which was severely affected by Hurricane Maria and suffered serious damage to production capacity. Production at the Puerto Rican plant is now steadily recovering. During this transition period, there was a certain level of supply constraints in the Chinese market for Rui Yining finished products, which are expected to last from 2 months to 3 months from now.
the company that called the "Communication Note" is Haizheng Pfizer Co., Ltd. Haizheng Pfizer said in the above-mentioned "communication note" that the current supply shortage is only temporary, the company will return to normal supply as soon as possible.
it is understood that Haizheng Pfizer is a subsidiary of Haizheng Pharmaceuticals, has been renamed Hanyu Pharmaceuticals. For this matter, "Securities Daily" reporter also called Haizheng Pharmaceuticals Secretary Shen Xifei, its introduction to reporters, Rui Yining big packaging in Pfizer's Potogo plant for production, and then imported into the domestic, in Pfizer's Dalian plant for sub-packaging, starting in June, because of Pfizer's Bododo Ligo factory packaging production problems, several batches of quality problems, not released, so there is a phase of out-of-stock. Already in the re-scheduling, production, the next batch of foreign factories can be released smoothly, the finished product is expected to be available to the market in November.Haizheng Pfizer has changed its name
It is understood that Rui Yining's generic name is Gretium-controlled tablets, listed in China in 1993, mainly for people with type 2 diabetes.
is a joint venture between Haizheng Pharmaceuticals and Pfizer, an A-share listed company. Haizheng Pfizer was formed in 2012 by Pfizer Luxembourg S.R.l in a joint venture with Haizheng Pharmaceuticals and its controlling subsidiary Haizheng Pharmaceuticals (Hangzhou) Co., Ltd. to develop, produce and promote branded generics for China and the global market.
November 11, 2017, Haizheng Pharmaceuticals announced that Pfizer Luxembourg Sarl ("Pfizer") transferred 49% of its interest in Haizheng Pfizer to its affiliate HPPC Holding S.?r.l.
Haizheng Pharmaceuticals said that after the disposal of Pfizer's shares, no longer hold a stake in Haizheng Pfizer, while Haizheng Pfizer's position as a controlling subsidiary of the company remains unchanged, GaoZheng Capital will become the company's new joint venture at the Haizheng Pfizer level.
November 29, 2017, Haizheng Pharmaceuticals announced that the change in its stake in its controlling subsidiary, Haizheng Pfizer pharma Co., Ltd., involved the signing of a series of commercial contracts with Pfizer and other interested parties. Agreements signed by the parties include intellectual property licensing agreements, technology transfer agreements and product supply-related agreements relating to product localization, so that the joint venture retains the products that Pfizer intends to inject into the joint venture during the joint venture, in the case of Rui Yining.
also agreed that the joint venture, Haizheng Pfizer, would cease using trademarks or trade names related to Pfizer or Pfizer as soon as possible, for a maximum of twelve months (which may be extended for a further six months under certain conditions).
On June 30 this year, Haizheng Pharmaceuticals announced that it had received a notice from its controlling subsidiary, Haizheng Pfizer, that the name "Haizheng Pfizer Co., Ltd." had been changed to "Hanyu Pharmaceutical Co., Ltd." with the approval of the Fuyang District Market Supervision Authority of Hangzhou City.
break up with Pfizer, is there a connection with Reynin out of stock? Haizheng Pharmaceuticals Secretary Shen Xifei also stressed to reporters that there is no relationship between the two.Product Supply Concerns
Haizheng Pharmaceuticals released its 2018 semi-annual report showing that the company achieved operating income of 5.331 billion yuan, down 3.16% from the same period last year, mainly due to the company has not yet received the EU release notice in the first half of the year and the two-vote system after the original Pfizer products due to direct sales decline.
Haizheng Pharmaceuticals, the company realized net profit attributable to the owners of the parent company of 0.15 billion yuan, an increase of 9.93 percent over the same period last year, mainly due to the company's first half of the year to obtain government subsidies and other non-operating income increased year-on-year. However, after deducting non-recurring gains and losses, Haizheng Pharmaceuticals achieved a net profit of 62.63 million yuan, compared with a loss of 725.65 million yuan in the same period last year.
Pfizer's exit, the development of Hanyu Pharmaceuticals has also attracted investors' attention.
Haizheng Pharmaceuticals, Hanyu Pharmaceuticals in the first half of 2018 continued to maintain steady growth in performance, the company adhering to the "patient first, quality-based, innovative change, the pursuit of excellence, integrity and compliance, growth and win-win" cultural philosophy, strengthen the construction of market and academic platforms, expand the grass-roots and retail market business, the use of digital tools to improve promotion efficiency and per capita productivity, the company achieved IMS ranking in the first half of the year up 7 places compared to the same period last year. At the same time, completed the company's industrial and commercial name change, other change of name work in an orderly manner, to achieve the full launch of Pfizer product real estate project, the first Pfizer original real estate products "Rose Man" began commercial production and supply, special star sub-packaging transfer equipment has been all in place;
first half of this year, Hanxuan Pharmaceuticals achieved operating income of 2.03 billion yuan, net profit attributable to the parent company of about 389 million yuan. In the same period in 2017, Haizheng Pfizer achieved revenue of RMB2 billion and net profit attributable to the parent company of RMB275 million.
it is worth mentioning that supply risk has always been the focus of attention. Haizheng Pharmaceuticals said in its 2018 semi-annual report that the company's pharmaceutical business includes the pure sales, distribution and retail business of third-party pharmaceuticals (including chain pharmacies, e-commerce, etc.) and the controlling subsidiary Hanyu Pharmaceuticals in the sale and promotion of its own preparation products and the pharmaceutical products business of former shareholder Pfizer exclusively authorized company (the business will be converted into the company's own preparation business after Hanyu Pharmaceuticals completes the transfer of real estate technology).
Haizheng Pharmaceuticals said that if the company's pharmaceutical business required the main product varieties are insufficient and can not be resolved in the short term, it may have a negative impact on the company's market share, sales revenue and net profit.
, Haizheng Pharmaceuticals out of stock, performance has fluctuated significantly. Tejising is an important variety sold by Haizheng Pfizer (now Hanyu Pharmaceuticals), which has been affected by supply from Pfizer's Italian plant since 2015, resulting in a significant drop in sales of the product. Teji star's cut-off also has a impact on the performance of Haizheng Pharmaceuticals.
2014, Haizheng Pharmaceuticals realized net profit attributable to shareholders of listed companies of RMB307.89 million, while in 2015, the company's net profit fell to RMB13,566.7 million, and in 2016, the Company's net profit was RMB94.428 million. (Securities Daily)